Study to Evaluate the Efficacy and Safety of "Allergovac Poliplus" in Polysensitized Patients With Allergic Rhinitis/Rhinoconjunctivitis, With or Without Asthma

Launched by ROXALL MEDICINA ESPAÑA S.A · Jan 28, 2019

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients aged between 5 and 60 years with allergic rhinitis or rhinoconjunctivitis mediated by IgE, caused by sensitization to more than one allergenic source (pollens or mites) and with or without associated mild / moderate asthma.
• • 2. Patients susceptible to receive treatment with Allergovac Poliplus (SCIT), according to usual clinical practice
• • 3. Patients who have given their signed informed consent.
• Exclusion Criteria:
• • 1. Patients who have received or initiated treatment with Allergovac Poliplus previously to study inclusion.
• • 2. Patients who have received previous immunotherapy treatment, both subcutaneous (SCIT) and sublingual (SLIT), with any of the allergenic extracts that they plan to receive, in the 5 years prior to study inclusion.
• • 3. Patients who in the opinion of the investigator may present difficulties that prevent the understanding of what was written in the informed consent form or the completion of self-administered questionnaires / scales or the patient's diary.
• • 4. Patients who are participating in another clinical trial or observational study with any drug.